Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22483444 | 1.00 | TSHR (0.32) | TSHRCNR1CNR2PTPN1PTPN6 | |
| SCHEMBL22483585 | 0.98 | TSHR (0.31) | TSHRCNR1CNR2 | |
| SCHEMBL22483591 | 0.94 | TSHR (0.31) | TSHRCNR1CNR2PTPN1PTPN6 | |
| SCHEMBL22483443 | 0.94 | TSHR (0.31) | TSHRCNR1CNR2PTPN1PTPN6 | |
| SCHEMBL22483716 | 0.94 | TSHR (0.30) | TSHR | |
| SCHEMBL22484023 | 0.92 | TSHR (0.30) | TSHR | |
| SCHEMBL22483576 | 0.92 | TSHR (0.32) | TSHRCNR1CNR2MTNR1BMTNR1A | |
| SCHEMBL26245488 | 0.91 | CNR1 (0.32) | TSHRCNR1CNR2 | |
| SCHEMBL22484021 | 0.91 | TSHR (0.31) | TSHRCNR1CNR2 | |
| SCHEMBL22484154 | 0.91 | ESR1 (0.34) | TSHRCNR1CNR2MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | DIC CORPORATION (JP) | 2023-09-19 | — | — | US | disclosed |
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | DIC CORPORATION (JP) | 2023-09-19 | — | — | US | disclosed |
| US-20200308488-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT IN WHICH THE COMPOUND IS USED | DIC CORPORATION (JP) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | SFXN1, SFXN3, SIK3 | TSHR 2186/4885CNR1 199/4885CNR2 584/4885 |
| US-20200308488-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT IN WHICH THE COMPOUND IS USED | SFXN1, SFXN3, SIK3 | TSHR 2186/4885CNR1 199/4885CNR2 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.